Glenmark Pharmaceuticals Ltd. has sealed a licensing deal with peer Torrent Pharmaceuticals Ltd. for its novel sodium glucose co-transporter-2 (SGLT2) inhibitor, remogliflozin etabonate, as it pursues rapid market expansion for the diabetes therapy in India.
This is potentially the first of such alliances as Glenmark seeks to shake up the SGLT2 inhibitor segment, emulating what...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
